The presence of inflammation and particularly CD8+ effector T cells in CM may predict a favorable clinical response to immune checkpoint inhibitors (ICI), additionally reinforcing the important role the immune system plays in melanoma (11). The gene discussed is CD8A; the disease is melanoma.